Please login to the form below

Not currently logged in

INC Research and DrugDev collaborate to push clinical trials

Aims to create cloud-based solutions to boost efficacy

INC Research logo 

Global content research organisation INC Research has entered a strategic collaboration with DrugDev to push increased efficacy in clinical trials via enhanced access to data.

Under the new agreement, INC will become the first CRO to complete integration with DrugDev's SiteCloud platform. SiteCloud enables users to make evidence-driven site selection decisions.

Clare Grace, VP site and patient access at INC Research, said: “INC Research is continuously looking to advance clinical research and patient and site engagement through innovation.

“DrugDev provides cutting edge solutions that help drive the biopharmaceutical industry forward. Cloud-based offerings like SiteCloud are the latest examples of the tools and resources INC Research uses to share critical investigative site data with our customers and drive increased efficiencies at critical points along the drug development continuum.”

As part of the collaboration, INC will continue to work with DrugDev on implementing additional innovative technologies that could improve clinical development and bring new medicines to patients faster.

Ibraheem Mahmood, president and CEO of DrugDev, added: “Real change will only come to the clinical research industry through meaningful collaboration and the widespread adoption of technology standards, so naturally we could not be more excited to work with INC research on this essential initiative.”

Article by
Kirstie Pickering

28th April 2015

From: Research, Marketing



Featured jobs

Subscribe to our email news alerts


Add my company Conferences, Events and Exhibition Stands is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge